Plus Therapeutics, Inc. (NASDAQ: PSTV) disclosed today that its continuing ReSPECT Phase I trial has shown positive results. In the clinical trial, the firm is assessing Rhenium NanoLiposome (RNL) in patients with recurrent glioblastoma (GBM). RNL is meant to deliver a very high dose of radiation directly into the brain tumor.

Plus Therapeutics is currently involved in the evaluation of RNL in Phase 1 dose-finding study called ReSPECT. The firm explained that the positive results from Phase I have confirmed that RNL is the new option for recurrent glioblastoma. PSTV notified that two patients have survived greater than 30 months after therapy with RNL.